PLG CPD Tutors

Sharon Finch

Sharon Finch is the CEO of Medius Associates, a specialised pharma business development consultancy group. Sharon has more than 30 years proven experience in business development having worked in-house at the Wellcome Foundation, Medeva plc and Ono Pharmaceutical Co. Ltd. prior to founding Medius in 1994.

Medius designs and runs in house BD training in a wide range of topics and Sharon chairs the PLG ITC course. She is Editor of the Business Development & Licensing Journal and is also a past Chairman of the UK Pharmaceutical Licensing Group Ltd and a past President of the European PLG Council.

Jill Ogden

Jill has over 26 years’ experience in the biopharmaceutical, healthcare and drug delivery industries, combining broad commercial experience with a strong scientific background.   Her key skills and achievements include:

  • A successful track record of concluding a wide range of transactions, including a corporate acquisition and technology/product licensing deals, establishing/developing partnerships and negotiating a wide range of commercial agreements on a global basis.
  • Strategic planning particularly associated with mergers and acquisitions.
  • Establishing and developing corporate business development functions, including market research, company profile/media relations activities, marketing strategy and IP portfolio management systems.

Jill has a PhD in Genetics and spent five years in molecular biology research at the Universities of Edinburgh and Oxford before joining Delta Biotechnology in 1987, where she held various R&D and project management positions covering a range of biopharmaceutical products and technologies. On leaving Delta in 1993, Jill co-founded a consultancy business specialising in the biopharmaceutical industry where she was involved in projects for US and European clients.

In 1996, Jill joined Andaris in business development and during the next 4 years was involved in two separate acquisitions; Andaris was first acquired by Quadrant Healthcare and then the enlarged Quadrant Group was acquired by Elan Corporation, where she was Director of Business Development. Throughout this time, Jill was involved in numerous licensing and product and technology divestment activities and finalised a range of deals on early stage products and technology platforms.

In 2003 Jill joined pSivida, an Australian NASDAQ-listed company, where she was Commercial Director with a broad range of business responsibilities focused on generating value from pSivida’s BioSilicon™ technology for drug delivery and product development applications. Since leaving pSivida in early 2007, Jill has been a business development consultant working for numerous international clients. During this time she has been involved in a range of transactions. Until recently she was a Board Director of Warwick Effect Polymers and its part time VP of Business Development, playing a leading role in the company’s acquisition.

Catharine Staughton

Catharine has a wide range of experience in the pharmaceutical and biotechnology industries gained over twenty years working in health care consulting, banking and industry.  She undertakes projects in a variety of areas and specialises in strategic assessments for acquisitions, portfolio reviews and project, deal and company valuations and is also experienced in supporting companies during fundraising activities. 

Catharine has a degree in Genetics from Cambridge and an MBA from Insead.  Catharine’s industry experience commenced with three years in the City at Robert Fleming’s broking division where she was an analyst covering European and US biotech stocks.  She speaks French well and has a working knowledge of German and Italian.

Stephen Reese

Stephen is a Partner in Olswang’s Intellectual Property Group and leads its Life Sciences practice.

Stephen advises clients on both contentious and non-contentious intellectual property matters including patents, trade marks, trade secrets and copyright. He represents and advises a broad range of clients in relation to the protection, exploitation and enforcement of their intellectual property rights.

He has significant experience representing those clients within the life sciences and technology fields on both contentious and non-contentious matters. Stephen has represented clients in significant patent litigation disputes including Boston Scientific and Lonza Biologics. He also has considerable experience in commercial transactions within the life sciences industry. He advises on research & development, licensing, disposals, acquisitions and due diligence activities and has acted on behalf of clients in highly successful and publicised collaboration transactions. In connection with his life sciences practice Stephen also advises clients on UK and EU regulatory matters.

Stephen is recognised for his expertise and has been described by Legal 500 as “astute” and “highly knowledgeable”. Stephen is currently an examiner for one of the papers for CIPA (Patent Attorneys) and ITMA (Trade Mark Attorneys) students and has given many external lectures on topics including IP audits, co-marketing and co-promotion agreements, research and development contracts and injunctions. He is also a tutor on the PLG’s Masters degree.

Jane Gaddum

With over 20 years healthcare experience at global pharmaceutical company AstraZeneca, BUPA Hospitals and the NHS, Jane Gaddum brings extensive experience in influencing decision-making in large complex organisations. Much of her career has been spent in the pharmaceutical industry, guiding product and corporate strategy and portfolio investment decisions at a global level, collaborating cross-culturally and cross functionally at the interface between Commercial, R&D and Business Development. She has held roles in emerging markets and global brand management; portfolio management across therapy areas; and as Vice President Emerging Brands, leading international marketing teams shaping the design, development and acquisition of new medicines for Asthma, COPD and Auto-immune diseases. She is passionate about ensuring the future needs of patients, physicians and those who fund healthcare, are built into phase 2 and 3 development plans.

Jane is currently a Non Executive Director and Chair of the Finance, Investment and Performance Committee for an NHS Trust, alongside running a textile business with a long trading history in silk yarns, bi-products and technical fibres. She also uses her extensive pharma experience on consultancy projects. Jane has a first degree in Agricultural Economics and an MBA from Henley Management College.

Anne Galer

Anne has worked in the pharmaceutical industry for 24 years in both the CRO sector and for several large pharma companies, having obtained a B.Sc. (Hons) in Agricultural Biochemistry and Nutrition from Newcastle University and an MPhil in Computer modelling of radionuclides in sheep from Nottingham University. Most of her time in the pharmaceutical industry has been spent in clinical development and project leadership roles in R&D. Anne’s project experience covers cardiovascular, inflammation and oncology therapeutic areas and she has a special interest in paediatric programmes having worked on paediatric programmes in cardiovascular, metabolic and oncology therapeutic areas.

Anne also has a strong interest in development of people and was involved in the development of an MSc course in Clinical Data Management. She has also held several External Examiner posts with universities for both BSc and MSc programmes in the pharmaceutical industry.

Mark Wilson

Mark Wilson has worked for GlaxoSmithKline and its predecessor companies for 16 years and has experience of both manufacturing and development in relation to primary processing, secondary processing and large-scale antibiotic production.

He has worked in a licensing role for several years and has negotiated and managed hundreds of collaborative development deals for a technology incubator within GSK that is focussed on novel secondary processing approaches. In relation to compound licensing, he has been an expert pharmaceutics reviewer on several due diligence visits, has co-drafted internal guidelines on negotiation approaches with regard to manufacturing and pre-clinical development activities, and has advised on such matters on approximately 30 major compound licence negotiations.

Jennifer Pierce

Jenny is a commercial lawyer, specialising in IP, with over 25 years of experience in the field.  She advises on all rights with an emphasis on strategy and transactions.

She is best known for her skill in monetising intellectual property, combining technical legal skills with a knowledge of the licensing business and international practice.  She has been nominated as a licensing expert by Intellectual Asset Management each year since the directory first appeared as the select IAM 250.

Janet Knowles

Janet is a Solicitor and Registered Technology Transfer Professional and has over 30 years’ experience of dealing with transactional IP in relation to all IP rights, but particularly in the science and technology fields. Janet is one of a limited number of UK IP licensing professionals recommended by the international guide IAM 1000 – Guide to the World’s Patent Practitioners (2018) and as an IP Star by Managing Intellectual Property.

Janet works with a wide range of clients but has particular expertise within the life sciences industry, in working with educational institutions and their spin-out companies and in the anti-trust issues of IP commercialisation.

Janet covers commercial life sciences transactions including their regulatory and IP implications. Her work ranges from early R&D phases and clinical trials to licensing, clinical and commercial manufacturing and supply and beyond. Her experience includes advising on: R&D, clinical trials and related CRO agreements; in-licensing; dossier and associated brand acquisitions.

Training Contact

Linda Sterrett

Tel: +44 7732 194819


Upcoming Training Events